[📢PSCC : Let’s collaborate at the heart of innovation in oncology 🚀]
DOWNLOAD PRESS RELEASE 🚀 Let’s collaborate at the heart of innovation in oncology. 🚀 Thrilled to share that Brenus Pharma is now part of the Paris Saclay Cancer Cluster (PSCC) (PSCC), the first national #Oncocluster! 🌐 We are proud to be part of the national and European oncology innovation ecosystem. By combining PSCC’s strengths and Brenus’ technology, we aim to foster #collaborations and accelerate our shared mission to improve #patient care. ➡️ Excited to contribute to PSCC’s collective ambition in reshaping the future of oncology! 🌍💪 #BrenusPharma #OncologyInnovation #PSCC #NextGenerationEU
[📢Stimulated Tumor Cells (STC) vaccine induces response in colorectal cancer #SITC23]
DOWNLOAD PR 🔬#SITC23 Thrilled to share new results we presented at the Society for Immunotherapy of Cancer (SITC) Congress! 🌎 Many thanks to all contributors, Céline Gongora Corentin Richard Romain Boidot Tanguy Fortin Alban Bessede Yan WANG Italiano Antoine Based on these vaccine characterization and preclinical, in-ovo and ex-vivo efficiency data, STC-1010 treatment will soon be evaluated for the first time in clinical trial in advanced metastatic stage of colorectal cancer in 2024.
SITC 2023 Annual meeting
Stimulated tumor cells (STC) vaccine induce response in colorectal cancer A. Italiano et al, J for ImmunoTherapy of Cancer, 2023 http://dx.doi.org/10.1136/jitc-2023-SITC2023.1132 Link to Poster DOWNLOAD PRESS RELEASE
[#NEXTHealthcare] The NEXT Roadshow is only a week away! 🎉
Thank you to Business France North America to give us this great opportunity to continue dusicussions and connect again with wonderful North American ecosystem 💬 #biotech #pharma Congratulations to all the innovated company selected ! ➡️ We are getting ready to share this week with strong #healthcare actors. [#NEXTHealthcare] The NEXT Roadshow is only a week away! 🎉 🗓️ Between October 16-20, the acceleration program participants will travel to Montreal and Boston to meet potential investors, gain insights from industry leaders and connect with like-minded professionals. Montreal (October 16-17): 💡 Speed meetings with Venture Capitalists. 💼 B2B meetings to forge valuable partnerships. 🌃 A delightful networking night to embrace the vibrant Canadian ecosystem, hosted by our partner Dentons Boston (October 18-20): 🏙️ A visit of Kendall Square, regarded as the health sciences innovation district of the US. 🌟 A networking night to dive into the dynamic US ecosystem hosted by EY 🎤 A pitch session to captivate potential investors hosted by CIC (Cambridge Innovation Center) #Roadshow French Healthcare Louis Malatrait Flavio Carratu Brenus Pharma Algoscope Aurora Sterilisation AXELIFE Intradys INSTITUT DE BIOTECHNOLOGIES JACQUES BOY Vibiosphen Ensweet – solutions de téléréadaptation HypnoVR and Thess Corporate
Join us at #Sachs_BEF
🔬 Dive into the future of cancer treatment! Join us on the 21st of September, 2023 for the ‘Advances in Immuno-Oncology’ panel at the 23rd Annual Biotech in Europe Forum (#Sachs_BEF) 🌍 Mark your calendar and learn about the latest breakthroughs in immuno-oncology from leading industry experts! 📆🎗️ Co-Chaired by: Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG Ekaterina Smirnyagina Smirnyagina, Senior Partner (Life Sciences), Oxford Science Enterprises Panellists: Luc Boblet Co-Founder & CEO, Egle Therapeutics SAS Pascal Winnen Neuville, CEO, DOMAIN Therapeutics SA Paul Bravetti, CEO, Brenus Pharma Per Norlén, CEO, Evaxion Biotech A/S
Panel participation at 23rd Biotech in Europe forum
Paul BRAVETTI ⬇️ “Two enlightening days at the Sachs Associates 23rd BIOTECH IN EUROPE FORUM have left me both #proud and #inspired. 📈 Being part of the “Major advances in immuno-oncology” panel, we delved deep into this year’s progress in this ever-evolving field with a palpable excitement around clinical data, science insights, and the promising directions we’re heading with such approaches. 🔬While we’re making strides with innovative therapies and tools, the ultimate focus remains on translating these into tangible patient benefits. Our shared mission remains to emphasized the pivotal role of understanding the nuanced biology and ensuring it aligns with patient needs. Every step of our work is aimed at optimizing efficacy while also managing expectations, and manufacturing challenges. ☑️ Many thanks to Esteban Pombo-Villar, and Hans Herklots for chairing, and Gerben Moolhuizen, Luc Boblet, Pascal Neuville, Seth Goldblum with whom I had the pleasure of sharing this discussion. Lastly, thank you to the SACHS for their hosting and organization. Such moments solidify my belief in the bright future of immuno-oncology and biotechnology 🟣” Brenus Pharma #CancerResearch #ImmunoOncology #Biotech #Innovation #SACHSForum
ONCO STARTUP SUMMIT : Le vécu de la startup “Quelle situation et perspective 2024 du marché de l’investissement pour les startups en oncologie”
REPLAY “REGARDS CROISES”
🎧Paul Bravetti, CEO Brenus Pharma – Taking the risk of launching a biotech company – Pharma Minds Podcast
LISTEN PODCAST “Paul a commencé sa carrière dans les Big Pharma (Servier, Takeda oncologie) il est parti à l’international, pour finalement se lancer dans une aventure entrepreneuriale en Biotech. Son goût de la science, du médical et de l’innovation au service des patients l’ont poussé à faire le grand saut. Depuis 3 ans, il alterne entre levées de fonds, construction d’une équipe engagée et développement du protocole pré-clinique au service de son candidat vaccin en oncologie. Nathalie Lahitte et Paul ont parlé de : -Son choix d’aller en Asie, -Travailler son switch médical -L’intrapreneuriat dans les Big Pharma -Devenir pionnier dans la recherche médicale -Préparer le pipeline de demain des Big Pharma -Comment décider de se lancer dans une aventure si risquée Témoignage rare sincère et suffisamment transparent pour donner envie de se plonger dans son mindset d’entrepreneur français au service de la science. Citation “La vraie générosité envers l’avenir consiste à tout donner au présent” Albert Camus.
[📢Brenus annouces its international scientific committee]
LYON, (FRANCE), June 7th, 2023, – Following the American Society of Clinical Oncology’s, Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow”, the company highlighted its international scientific committee. View PDF
ASCO annual meeting 2023
Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models F.Ghiringhelli et al, J Clin Oncol, 2023 (suppl 16; abstr e14661) 10.1200/JCO.2023.41.16_suppl.e14661 Link to Abstract